Norstella and Citeline Merge to Create $5B Global Pharma Technology Company

NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX Ltd

October 30, 2025

Biotechnology

Swiss-based NLS Pharmaceutics Ltd. merged with clinical-stage cell therapy company Kadimastem Ltd. to create a combined Nasdaq-listed biotechnology company named NewcelX Ltd. The merger closed effective October 30, 2025, with the new company beginning trading on the Nasdaq Capital Market on October 31, 2025 under ticker “NCEL.”

NLS Pharmaceutics to Merge with Kadimastem to Form NewcelX

June 27, 2025

Biotechnology

NLS Pharmaceutics (NASDAQ: NLSP) and Kadimastem (TASE: KDST) are progressing with their proposed merger, which would combine their CNS biopharmaceutical and off-the-shelf allogeneic cell therapy pipelines into a Nasdaq-traded company named NewcelX. The transaction is supported by financing actions (including equity financings and a $25 million committed equity facility) and shareholder approvals, with the companies targeting completion in early Q3 2025.

Warburg Pincus and Mubadala Acquire Pharma Intelligence from Informa

June 1, 2022

Data & Analytics

Warburg Pincus, joined by Mubadala Investment Company, completed the acquisition of Pharma Intelligence (the Citeline suite and related specialist brands) from Informa PLC, with Informa retaining a 15% equity stake. The investors said they will invest in product development and innovation to expand Pharma Intelligence's position in the pharmaceutical data and analytics market; Jay Nadler was appointed Executive Chair following completion.

Norstella Formed by Uniting Evaluate, MMIT, Panalgo and The Dedham Group

May 3, 2022

Healthcare Services

Four life‑sciences solutions providers — Evaluate, MMIT, Panalgo and The Dedham Group — have united under the new organization Norstella to combine data, analytics, software and market‑access consulting to speed patient access to therapies. The move creates an integrated platform offering commercial intelligence, market access insights and healthcare analytics to pharmaceutical manufacturers and other life‑sciences customers.

Elligo Health Research Acquires ClinEdge in $135M Transaction

September 23, 2021

Healthcare Services

Elligo Health Research completed the acquisition of ClinEdge (including GuideStar Research and BTC of New Bedford) as part of a $135 million financing led by Morgan Stanley Expansion Capital and Ally Bridge Group, with participation from Norwest Venture Partners and existing investors. The deal expands Elligo’s global scale and capabilities by combining ClinEdge’s research practice management and clinical services with Elligo’s IntElligo technology, EHR-derived data access, and trial-acceleration platform.

Nordic Capital and Astorg Acquire Cytel from New Mountain Capital

December 21, 2020

Healthcare Services

Nordic Capital and Astorg have agreed to jointly acquire Cytel Inc. from New Mountain Capital. Cytel, a Waltham, Massachusetts–based provider of clinical trial design software, biometrics services and advanced analytics with more than 1,500 employees, will continue to be led by CEO Josh Schultz while the new owners invest to accelerate product development and growth; terms were not disclosed.